EA200200095A1 - Новые нафтилсульфоновые кислоты и родственные соединения в качестве агонистов поглощения глюкозы - Google Patents
Новые нафтилсульфоновые кислоты и родственные соединения в качестве агонистов поглощения глюкозыInfo
- Publication number
- EA200200095A1 EA200200095A1 EA200200095A EA200200095A EA200200095A1 EA 200200095 A1 EA200200095 A1 EA 200200095A1 EA 200200095 A EA200200095 A EA 200200095A EA 200200095 A EA200200095 A EA 200200095A EA 200200095 A1 EA200200095 A1 EA 200200095A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- nrc
- compounds
- naphthyl
- alkyl
- acids
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title abstract 2
- 150000007513 acids Chemical class 0.000 title abstract 2
- 239000008103 glucose Substances 0.000 title abstract 2
- 238000010521 absorption reaction Methods 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000003746 Insulin Receptor Human genes 0.000 abstract 2
- 108010001127 Insulin Receptor Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 230000003178 anti-diabetic effect Effects 0.000 abstract 2
- 239000003472 antidiabetic agent Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 206010007134 Candida infections Diseases 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/51—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/57—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton
- C07C309/59—Nitrogen analogues of carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Раскрываются способы лечения состояний, ассоциированных с гипергликемией, особенно диабета типа II, с применением новых нафтилсульфоновых кислот и родственных соединений. Соединения формулы (I), где Rи Rозначают независимо друг от друга водород, алкил, замещенный алкил, арил, замещенный арил, Rозначает заместитель в кольце В и означает -SOOR, -C(O)OR, -SONR, -C(O)NRили тетразолил; линкер -WY- между нафтилом и фенилом отделяет кольцо А нафтила и означает независимо друг от друга -C(O)NR-, -NRC(O)-, -C(O)O-, -OC(O)-, -CH=CH-, -NRCH-, -CHNR-, -NRC(O)NR-, -NRC(O)O-, -OC(O)NR-, -NRSOO-, -OSONR-, -OC(O)O-, -SONR-, -NRSO-, -OSO- или -SOO-; Rи Rозначают каждый независимо друг от друга водород или (низший)алкил; необязательно в виде единственных стереоизомеров или смесей стереоизомеров, или их фармацевтически приемлемые соли применимы в способах стимуляции киназной активности рецептора инсулина, усиления активации рецептора инсулина с помощью инсулина и стимуляции поглощения глюкозы клетками. Раскрывается также ряд антидиабетических соединений и фармацевтических составов, содержащих антидиабетические соединения.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14644499P | 1999-07-29 | 1999-07-29 | |
| PCT/US2000/020909 WO2001012591A1 (en) | 1999-07-29 | 2000-07-28 | Novel naphthylsulfonic acids and related compounds as glucose uptake agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200200095A1 true EA200200095A1 (ru) | 2002-06-27 |
| EA006704B1 EA006704B1 (ru) | 2006-02-24 |
Family
ID=22517390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200200095A EA006704B1 (ru) | 1999-07-29 | 2000-07-28 | Нафтилсульфоновые кислоты и родственные соединения в качестве агонистов поглощения глюкозы |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6653321B1 (ru) |
| EP (1) | EP1200396A1 (ru) |
| JP (1) | JP2003507361A (ru) |
| KR (1) | KR100639544B1 (ru) |
| CN (1) | CN1282641C (ru) |
| AR (1) | AR031524A1 (ru) |
| AU (1) | AU773828B2 (ru) |
| BR (1) | BR0012836A (ru) |
| CA (1) | CA2377668C (ru) |
| CZ (1) | CZ2002234A3 (ru) |
| EA (1) | EA006704B1 (ru) |
| FR (2) | FR2796942B1 (ru) |
| HK (1) | HK1046268B (ru) |
| HU (1) | HUP0202168A3 (ru) |
| IL (2) | IL147032A0 (ru) |
| IT (1) | ITTO20000745A1 (ru) |
| MX (1) | MXPA02001023A (ru) |
| NO (1) | NO20020425L (ru) |
| NZ (1) | NZ516249A (ru) |
| PL (1) | PL353359A1 (ru) |
| TR (1) | TR200200250T2 (ru) |
| TW (1) | TWI256384B (ru) |
| UA (1) | UA74555C2 (ru) |
| WO (1) | WO2001012591A1 (ru) |
| ZA (1) | ZA200200128B (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2421581A1 (en) | 2000-09-07 | 2002-03-14 | Telik, Inc. | Benzene tricarboxylic acid amides as insulin receptor activators |
| US6528037B2 (en) | 2000-10-11 | 2003-03-04 | Telik, Inc. | Method for determining whether a compound is an insulin receptor kinase activator |
| EP2635559A2 (en) * | 2010-11-01 | 2013-09-11 | Neurotune AG | Neurotrypsin inhibitors |
| CN106800532A (zh) * | 2015-02-12 | 2017-06-06 | 佛山市赛维斯医药科技有限公司 | 一种含腈基喹啉结构的葡萄糖激酶活化剂及其用途 |
| CN106749010A (zh) * | 2015-02-12 | 2017-05-31 | 佛山市赛维斯医药科技有限公司 | 一类含喹啉和硝基苯结构的葡萄糖激酶活化剂及用途 |
| CN104592113A (zh) * | 2015-02-12 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | 含喹啉和腈基苯结构的葡萄糖激酶活化剂及用途 |
| CN106749002A (zh) * | 2015-02-12 | 2017-05-31 | 佛山市赛维斯医药科技有限公司 | 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途 |
| CN104557695A (zh) * | 2015-02-12 | 2015-04-29 | 佛山市赛维斯医药科技有限公司 | 含喹啉结构的葡萄糖激酶活化剂、制备方法及其用途 |
| CN104892505A (zh) * | 2015-02-12 | 2015-09-09 | 佛山市赛维斯医药科技有限公司 | 含卤代喹啉结构的葡萄糖激酶活化剂、制备方法及其用途 |
| CN104557698A (zh) * | 2015-02-12 | 2015-04-29 | 佛山市赛维斯医药科技有限公司 | 含喹啉基和烷氧苯基结构的葡萄糖激酶活化剂及用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH488212A (de) | 1967-09-01 | 1970-03-31 | Ciba Geigy | Photographisches Material |
| CA985675A (en) | 1971-04-07 | 1976-03-16 | Ciba-Geigy Ag | Azo dyestuffs, their manufacture and use |
| US4118232A (en) | 1971-04-07 | 1978-10-03 | Ciba-Geigy Ag | Photographic material containing sulphonic acid group containing disazo dyestuffs |
| US4051176A (en) * | 1976-05-10 | 1977-09-27 | American Cyanamid Company | Ureidophenylenebis(carbonylimino)dinaphthalenetrisulfonic acid compounds |
| US4129591A (en) | 1976-10-27 | 1978-12-12 | American Cyanamid Company | Ureida-phenylenebis(substituted imino)multianionic substituted dinaphthalene sulfonic acids and salts |
| US4102917A (en) * | 1977-06-01 | 1978-07-25 | American Cyanamid Company | Substituted phenyl naphthalenesulfonic acids |
| US4132730A (en) * | 1977-07-29 | 1979-01-02 | American Cyanamid Company | Ureylene naphthalene sulfonic acids |
| US4120891A (en) | 1977-07-01 | 1978-10-17 | American Cyanamid Company | Ureylene naphthalene sulfonic acids |
| US4229371A (en) * | 1977-07-29 | 1980-10-21 | American Cyanamid Company | Ureylene naphthalene sulfonic acid intermediates |
| AU2226092A (en) | 1991-06-14 | 1993-01-12 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Azo-dye derivatives exhibiting anti-hiv activity |
| US5589510A (en) | 1994-06-02 | 1996-12-31 | Fuji Immunopharmaceuticals Corp. | Method for inhibiting retroviral infection by administering a naphthalenesulfonic acid compound |
| DE19521589A1 (de) | 1995-06-14 | 1996-12-19 | Bayer Ag | Polyfunktionelle Azoreaktivfarbstoffe |
| ATE296446T1 (de) * | 1997-01-15 | 2005-06-15 | Telik Inc | Modulatoren von insulinrezeptor-aktivität |
-
2000
- 2000-07-28 IL IL14703200A patent/IL147032A0/xx active IP Right Grant
- 2000-07-28 NZ NZ516249A patent/NZ516249A/xx unknown
- 2000-07-28 CA CA002377668A patent/CA2377668C/en not_active Expired - Fee Related
- 2000-07-28 JP JP2001516892A patent/JP2003507361A/ja not_active Withdrawn
- 2000-07-28 HK HK02107735.3A patent/HK1046268B/zh not_active IP Right Cessation
- 2000-07-28 EP EP00952351A patent/EP1200396A1/en not_active Withdrawn
- 2000-07-28 WO PCT/US2000/020909 patent/WO2001012591A1/en not_active Ceased
- 2000-07-28 KR KR1020027001279A patent/KR100639544B1/ko not_active Expired - Fee Related
- 2000-07-28 UA UA2002021548A patent/UA74555C2/uk unknown
- 2000-07-28 PL PL00353359A patent/PL353359A1/xx not_active IP Right Cessation
- 2000-07-28 FR FR0009979A patent/FR2796942B1/fr not_active Expired - Fee Related
- 2000-07-28 MX MXPA02001023A patent/MXPA02001023A/es active IP Right Grant
- 2000-07-28 US US09/628,206 patent/US6653321B1/en not_active Expired - Fee Related
- 2000-07-28 AR ARP000103918A patent/AR031524A1/es unknown
- 2000-07-28 AU AU65066/00A patent/AU773828B2/en not_active Ceased
- 2000-07-28 CN CNB008109060A patent/CN1282641C/zh not_active Expired - Fee Related
- 2000-07-28 HU HU0202168A patent/HUP0202168A3/hu unknown
- 2000-07-28 EA EA200200095A patent/EA006704B1/ru not_active IP Right Cessation
- 2000-07-28 TR TR2002/00250T patent/TR200200250T2/xx unknown
- 2000-07-28 IT IT2000TO000745A patent/ITTO20000745A1/it unknown
- 2000-07-28 TW TW089115112A patent/TWI256384B/zh not_active IP Right Cessation
- 2000-07-28 BR BR0012836-8A patent/BR0012836A/pt not_active Application Discontinuation
- 2000-07-28 CZ CZ2002234A patent/CZ2002234A3/cs unknown
-
2001
- 2001-12-11 IL IL147032A patent/IL147032A/en not_active IP Right Cessation
-
2002
- 2002-01-07 ZA ZA200200128A patent/ZA200200128B/xx unknown
- 2002-01-28 NO NO20020425A patent/NO20020425L/no unknown
- 2002-11-08 FR FR0214025A patent/FR2830531B1/fr not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20070984L (no) | Dihydropterididinon infusjonslosning som har en lang lagringstid | |
| US20060004093A1 (en) | Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto | |
| KR101718596B1 (ko) | 티에닐[3,2-d]피리미딘-4-온 화합물, 그 제조방법, 약물조성물 및 용도 | |
| ES2572148T3 (es) | Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados | |
| CN103228655A (zh) | 咔唑和咔啉衍生物，及其制备方法和治疗应用 | |
| CZ20024003A3 (cs) | Deriváty acylfenylmočoviny, způsoby jejich výroby a použití jako léčiva | |
| ES2566973T9 (es) | Uso de SNS-595 para tratar leucemia | |
| EA200200095A1 (ru) | Новые нафтилсульфоновые кислоты и родственные соединения в качестве агонистов поглощения глюкозы | |
| US8440827B2 (en) | Photolabile caged transition metal complexes and methods of using the same | |
| CN116514783A (zh) | 三嗪衍生物 | |
| AU2016382372A1 (en) | Sulfonamide derivative and preparation method and use thereof | |
| Seidel et al. | Synthesis, structures, reactivity and medicinal chemistry of antitubercular benzothiazinones | |
| NO20051901L (no) | Nye antimycobakterielle sammensetninger og pyrrole derivater som antimycobakterielle sammensetninger | |
| AR042547A1 (es) | Uso de acidos alfa - feniltiocaboxilico y alfa - feniloxicarboxilico con actividad disminuidora de la glucosa en el suero y de los lipidos en el suero | |
| RU2005100761A (ru) | Амидзамещенные производные ксантина, обладающие модуляторной активностью в отношении биосинтеза глюкозы из неуглеводных субстратов | |
| BR0318533A (pt) | azolidinacarbonitrilas e seu uso como inibidores de dpp-iv | |
| US20040198777A1 (en) | Ligands of adenine nucleotide translocase (ANT) and compositions and methods related thereto | |
| MX9405111A (es) | Nuevos derivados de (1-fenil-1-heterociclil)metanol y(1-fenil-1-heterociclil-metilamina). | |
| MX9304403A (es) | Derivados farmacologicamente activos de ó-(aminometilo terciario)-bencenmetanol | |
| PT90475B (pt) | Processo para a preparacao de pro-farmacos de 2',3'-didehidro-2',3'-didesoxinucleosidos com accao anti-viral | |
| US20030055090A1 (en) | Antivesicant compounds and methods of making and using thereof | |
| ES2070959T3 (es) | Utilizacion de derivados del bis(4-hidroxifeniltio)metano en el tratamiento de la diabetes mellitus. | |
| NO20022290L (no) | Aryloksypropanolaminer for forbedring av husdyravl | |
| MX9305300A (es) | Nuevos derivados de 3-oxadiazolil-1-6-naftiridina y proceso para supreparacion. | |
| ES8800938A1 (es) | Procedimiento para preparar derivados berbanicos biologicamente activos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |